SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma

CAR-T Digest - August 2020

03 June 2026: SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma

SOTIO announced that the U.S. FDA has granted Orphan Drug Designation to SOT106 for the treatment of osteosarcoma, highlighting the potential of this next-generation LRRC15-targeting antibody-drug conjugate in a disease with significant unmet medical need
Building on this momentum, SOT106 is advancing toward its first-in-human study in the second half of 2026, positioning the company to generate an early clinical proof-of-concept in a disease where therapeutic innovation has remained largely stagnant for decades
Preclinical data further strengthens the investment case, with SOT106 demonstrating robust anti-tumor activity in both osteosarcoma and soft tissue sarcoma models alongside favorable tolerability, suggesting the potential for a high therapeutic index and best-in-class positioning within the emerging LRRC15 ADC landscape
SOT106 is a next-generation ADC targeting leucine-rich repeat-containing 15, a clinically validated target broadly expressed in sarcoma tumors and tumor-associated stroma, enabling a differentiated therapeutic approach for both osteosarcoma and soft tissue sarcomas
Strategically, the orphan designation not only strengthens development through regulatory incentives and potential market exclusivity but also establishes SOT106 as a program to watch in sarcoma, where positive early clinical data could unlock expansion opportunities across multiple solid tumors and elevate LRRC15 as a next-generation ADC target